FDA Advisory Panel Endorses Grail's Multi-Cancer Early Detection Blood Test On Wednesday, September 23, 2026, an FDA advisory panel voted 7-2 (with one abstention) to endorse Grail Inc.'s Galleri blood test, which screens for signals of over 50 types of cancer in healthy adults aged 50 and older. While the panel acknowledged the test's potential to identify cancers without existing screenings, it warned that the test is not a replacement for routine screenings and lacks evidence of reducing cancer deaths. The FDA will make a final decision on approval in a few months, which could lead to increased availability through Medicare and private insurance coverage.

FDA Advisory Panel Endorses Grail's Multi-Cancer Early Detection Blood Test On Wednesday, September 23, 2026, an FDA advisory panel voted 7-2 (with one abstention) to endorse Grail Inc.'s Galleri blood test, which screens for signals of over 50 types of cancer in healthy adults aged 50 and older. While the panel acknowledged the test's potential to identify cancers without existing screenings, it warned that the test is not a replacement for routine screenings and lacks evidence of reducing cancer deaths. The FDA will make a final decision on approval in a few months, which could lead to increased availability through Medicare and private insurance coverage.

FDA Advisory Panel Endorses Grail's Multi-Cancer Early Detection Blood Test On Wednesday, September 23, 2026, an FDA advisory panel voted 7-2 (with one abstention) to endorse Grail Inc.'s Galleri blood test, which screens for signals of over 50 types of cancer in healthy adults aged 50 and older. While the panel acknowledged the test's potential to identify cancers without existing screenings, it warned that the test is not a replacement for routine screenings and lacks evidence of reducing cancer deaths. The FDA will make a final decision on approval in a few months, which could lead to increased availability through Medicare and private insurance coverage.